

**GOVERNMENT OF INDIA
MINISTRY OF HEALTH AND FAMILY WELFARE
DEPARTMENT OF HEALTH AND FAMILY WELFARE**

**LOK SABHA
UNSTARRED QUESTION NO. 3949
TO BE ANSWERED ON 24th March, 2023**

DEMAND OF “RIBOCICLIB” MEDICINE

3949.DR. SHASHI THAROOR:

Will the Minister of **HEALTH AND FAMILY WELFARE** be pleased to state:

- (a) whether the Government has information on the market price and demand of the life-saving medicine “Ribociclib” used in the treatment of hormone-related breast cancer and if so, the details thereof and if not, the reasons therefor;
- (b) whether the supply of Ribociclib is commensurate with its demand in the country and if so, the details thereof and if not, the reasons therefor;
- (c) whether the Government has or plans to formulate any scheme to ensure the availability of Ribociclib at a reasonably affordable price under the National Cancer Control Programme and if so, the details thereof and if not, the reasons therefor; and
- (d) whether the Indian Council of Medical Research maintains the data concerning each category of breast cancer cases registered in India and publish it on its website and if so, the details thereof and if not, the reasons therefor?

**ANSWER
THE MINISTER OF STATE IN THE MINISTRY OF HEALTH AND FAMILY
WELFARE**

(DR. BHARATI PRAVIN PAWAR)

- (a) The Department of Pharmaceuticals has informed that as per Pharmatrac database of February 2023, only one brand is reported for Ribociclib medicine. Its Maximum Retail Price is Rs. 23,625/- per pack.
- (b) The data is not maintained centrally.
- (c) National Pharmaceutical Pricing Authority vide order S.O. 1041(E) dated 27th February, 2019, has put a cap on Trade Margin of 42 selected non-scheduled anti-cancer medicines on pilot basis under ‘Trade Margin Rationalization’ approach. Ribociclib was also included in this.
- (d) The National Cancer Registry Programme (NCRP) under the National Centre for Disease Informatics and Research, Indian Council of Medical Research (ICMR-NCDIR) with its

network of cancer registries provides the data on cancer incidence, mortality, pattern, trend and geo-pathological distribution of cancers including breast cancer. The breast cancer is the leading sites in 19 cancer registries. The report is published every two years and is available on <https://www.ncdirindia.org/>
